SUMO1 Modification Stabilizes CDK6 Protein and Drives the Cell Cycle and Glioblastoma Progression

Overview

Journal Nat Commun

Specialty Biology

Date 2014 Jun 24

PMID 24953629

Citations 73

Authors

Anita C Bellail

Jeffrey J Olson

Chunhai Hao

Affiliations

Soon will be listed here.

Abstract

Ubiquitination governs oscillation of cyclin-dependent kinase (CDK) activity through a periodic degradation of cyclins for orderly cell cycle progression; however, the mechanism that maintains the constant CDK protein levels throughout the cell cycle remains unclear. Here we show that CDK6 is modified by small ubiquitin-like modifier-1 (SUMO1) in glioblastoma, and that CDK6 SUMOylation stabilizes the protein and drives the cell cycle for the cancer development and progression. CDK6 is also a substrate of ubiquitin; however, CDK6 SUMOylation at Lys 216 blocks its ubiquitination at Lys 147 and inhibits the ubiquitin-mediated CDK6 degradation. Throughout the cell cycle, CDK1 phosphorylates the SUMO-specific enzyme, ubiquitin-conjugating enzyme9 (UBC9) that in turn mediates CDK6 SUMOylation during mitosis; CDK6 remains SUMOylated in G1 phase and drives the cell cycle through G1/S transition. Thus, SUMO1-CDK6 conjugation constitutes a mechanism of cell cycle control and inhibition of this SUMOylation pathway may provide a strategy for treatment of glioblastoma.

Citing Articles

The Cajal body marker protein coilin is SUMOylated and possesses SUMO E3 ligase-like activity.

Lett K, McLaurin D, Tucker S, Hebert M Front RNA Res. 2024; 1.

PMID: 39703804 PMC: 11656447. DOI: 10.3389/frnar.2023.1197990.

Non-Immune-Mediated, p27-Associated, Growth Inhibition of Glioblastoma by Class-II-Transactivator (CIITA).

Tan A, Henry A, Goffart N, Poulet C, Sluijs J, Hol E Cells. 2024; 13(22).

PMID: 39594630 PMC: 11593141. DOI: 10.3390/cells13221883.

SENP7 inhibits glioblastoma metastasis and invasion by dissociating SUMO2/3 binding to specific target proteins.

Zhang J, Zheng H, Liang P Open Med (Wars). 2024; 19(1):20241052.

PMID: 39381427 PMC: 11459272. DOI: 10.1515/med-2024-1052.

Distinctive tumorigenic significance and innovative oncology targets of SUMOylation.

Zhou H, Deng N, Li Y, Hu X, Yu X, Jia S Theranostics. 2024; 14(8):3127-3149.

PMID: 38855173 PMC: 11155398. DOI: 10.7150/thno.97162.

Stabilization of Pin1 by USP34 promotes Ubc9 isomerization and protein sumoylation in glioma stem cells.

Zhu Q, Liang P, Meng H, Li F, Miao W, Chu C Nat Commun. 2024; 15(1):40.

PMID: 38167292 PMC: 10762127. DOI: 10.1038/s41467-023-44349-x.

References

Schulze-Gahmen U, Kim S . Structural basis for CDK6 activation by a virus-encoded cyclin. Nat Struct Biol. 2002; 9(3):177-81. DOI: 10.1038/nsb756. View

Yu Q, Geng Y, Sicinski P . Specific protection against breast cancers by cyclin D1 ablation. Nature. 2001; 411(6841):1017-21. DOI: 10.1038/35082500. View

Bergink S, Jentsch S . Principles of ubiquitin and SUMO modifications in DNA repair. Nature. 2009; 458(7237):461-7. DOI: 10.1038/nature07963. View

Hoege C, Pfander B, Moldovan G, Pyrowolakis G, Jentsch S . RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature. 2002; 419(6903):135-41. DOI: 10.1038/nature00991. View

Reverter D, Lima C . A basis for SUMO protease specificity provided by analysis of human Senp2 and a Senp2-SUMO complex. Structure. 2004; 12(8):1519-31. DOI: 10.1016/j.str.2004.05.023. View

Matic I, Schimmel J, Hendriks I, van Santen M, van de Rijke F, van Dam H . Site-specific identification of SUMO-2 targets in cells reveals an inverted SUMOylation motif and a hydrophobic cluster SUMOylation motif. Mol Cell. 2010; 39(4):641-52. DOI: 10.1016/j.molcel.2010.07.026. View

Vassilev L, Tovar C, Chen S, Knezevic D, Zhao X, Sun H . Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc Natl Acad Sci U S A. 2006; 103(28):10660-5. PMC: 1502288. DOI: 10.1073/pnas.0600447103. View

Michaud K, Solomon D, Oermann E, Kim J, Zhong W, Prados M . Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res. 2010; 70(8):3228-38. PMC: 2855904. DOI: 10.1158/0008-5472.CAN-09-4559. View

Desterro J, Rodriguez M, Hay R . SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol Cell. 1998; 2(2):233-9. DOI: 10.1016/s1097-2765(00)80133-1. View

10.

Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

11.

Hu M, Deshpande A, Enos M, Mao D, Hinds E, Hu G . A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis. Cancer Res. 2009; 69(3):810-8. PMC: 2636510. DOI: 10.1158/0008-5472.CAN-08-2473. View

12.

Puyol M, Martin A, Dubus P, Mulero F, Pizcueta P, Khan G . A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell. 2010; 18(1):63-73. DOI: 10.1016/j.ccr.2010.05.025. View

13.

Yu Q, Sicinska E, Geng Y, Ahnstrom M, Zagozdzon A, Kong Y . Requirement for CDK4 kinase function in breast cancer. Cancer Cell. 2006; 9(1):23-32. DOI: 10.1016/j.ccr.2005.12.012. View

14.

Geiss-Friedlander R, Melchior F . Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol. 2007; 8(12):947-56. DOI: 10.1038/nrm2293. View

15.

Kim J, Choi H, Kim B, Kim M, Lee J, Kim I . Roles of sumoylation of a reptin chromatin-remodelling complex in cancer metastasis. Nat Cell Biol. 2006; 8(6):631-9. DOI: 10.1038/ncb1415. View

16.

Hay R . SUMO-specific proteases: a twist in the tail. Trends Cell Biol. 2007; 17(8):370-6. DOI: 10.1016/j.tcb.2007.08.002. View

17.

Gareau J, Lima C . The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat Rev Mol Cell Biol. 2010; 11(12):861-71. PMC: 3079294. DOI: 10.1038/nrm3011. View

18.

Malumbres M, Barbacid M . Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009; 9(3):153-66. DOI: 10.1038/nrc2602. View

19.

Bonne-Andrea C, Kahli M, Mechali F, Lemaitre J, Bossis G, Coux O . SUMO2/3 modification of cyclin E contributes to the control of replication origin firing. Nat Commun. 2013; 4:1850. PMC: 3674260. DOI: 10.1038/ncomms2875. View

20.

Golebiowski F, Matic I, Tatham M, Cole C, Yin Y, Nakamura A . System-wide changes to SUMO modifications in response to heat shock. Sci Signal. 2009; 2(72):ra24. DOI: 10.1126/scisignal.2000282. View